在淋巴结切除后,癌症免疫治疗反应仍然存在
bioRxiv : the preprint server for biology
|October 2, 2023
概括
手术切除瘤排水淋巴结并不会影响免疫检查点阻塞 (ICB) 反应. 遥远的淋巴结补偿,保持ICB治疗癌症患者的有效性.
科学领域:
- 免疫学 免疫学 免疫学
- 在瘤学瘤学.
- 手术瘤学手术瘤学
背景情况:
- 淋巴运输对于向淋巴结呈现癌症抗原至关重要,从而启动抗瘤免疫反应.
- 手术性淋巴结解剖在癌症治疗中很常见,但它对免疫疗法疗效的影响仍在争论中.
- 免疫检查点阻塞 (ICB) 疗法依赖于淋巴结内的T细胞激活.
研究的目的:
- 调查淋巴结解剖是否影响免疫检查点阻塞 (ICB) 的有效性.
- 为了确定替代性淋巴管道是否可以在去除瘤排水淋巴结 (tdLN) 后维持抗瘤免疫力.
- 评估在接受癌症手术和ICB的患者中非tdLN免疫反应的临床相关性.
主要方法:
- 在淋巴结解剖后,对黑色素瘤患者对PD-1阻塞的反应的分析.
- 黑色素瘤和乳腺癌的小鼠模型研究完整淋巴结切除后的ICB反应.
- 追踪可溶性抗原和树突细胞迁移到非直接瘤排水淋巴结 (非tdLNs) 的可溶性抗原和树突细胞迁移.
- 在头癌患者中,ICB反应与远程区域的反应性淋巴结存在的相关性.
主要成果:
- 黑色素瘤患者在淋巴结解剖后保持了对PD-1阻塞的反应.
- 在完全切除淋巴结后,小鼠模型证实了持续的ICB疗效.
- 在tdLN切除后,抗原呈现和树突细胞迁移成功地被重定向到非tdLN.
- 当远处的淋巴结在手术后反应时,头癌患者显示出显著的ICB反应.
结论:
- 完全切除淋巴结并不会取消免疫检查点封锁的有效性.
- 非直接的瘤排水淋巴结 (非tdLNs) 有效地补偿了瘤排水淋巴结 (tdLNs) 的去除.
- 遥远的淋巴结在维持全身抗瘤免疫力和手术后ICB治疗反应方面发挥着至关重要的作用.
相关概念视频
Tumor Immunotherapy
551
Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.
551
Cancer Vaccines
396
Cancer treatment vaccines are a rapidly evolving field that offers a promising approach to immunotherapy. Unlike traditional vaccines that prevent diseases, cancer treatment vaccines are designed to treat existing cancers by stimulating the immune system to recognize and attack cancer cells.
Cancer vaccines come in two categories: preventive (prophylactic) and treatment (active). Preventive vaccines, such as the Human Papillomavirus (HPV) vaccine, protect against viruses that cause certain...
Cancer vaccines come in two categories: preventive (prophylactic) and treatment (active). Preventive vaccines, such as the Human Papillomavirus (HPV) vaccine, protect against viruses that cause certain...
396
Cancer Stem Cells and Tumor Maintenance
5.0K
Early diagnosis and treatment can often cure cancer. However, even with treatment, residual cells called cancer stem cells (CSC) might remain, often causing tumor recurrence. These cancer stem cells possess the potential for self-renewal and multi-lineage differentiation and are often responsible for the therapeutic resistance displayed in most cancers.
Cancer stem cells are thought to originate from tissue-specific normal stem cells or progenitor cells. The normal stem cells usually reside in...
Cancer stem cells are thought to originate from tissue-specific normal stem cells or progenitor cells. The normal stem cells usually reside in...
5.0K
Treatment Resistant Cancers
3.3K
Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
3.3K
Cytotoxic T Cells-mediated Immune Response
956
Cytotoxic T cells are a vital component of the immune system. They have the remarkable ability to identify and target antigens on infected or abnormal cells. These antigens often originate from intracellular pathogens such as viruses or abnormal proteins cancer cells produce.
Immunological surveillance is the ability of immune cells to monitor and eliminate infected cells with intracellular pathogens, neoplastically transformed cells, and cells with non-self antigens. Cytotoxic T cells and NK...
Immunological surveillance is the ability of immune cells to monitor and eliminate infected cells with intracellular pathogens, neoplastically transformed cells, and cells with non-self antigens. Cytotoxic T cells and NK...
956


